

06 May 2009

**Northwest Biotherapeutics, Inc.**

(the "Company")

**Transfer of Shares from Reg S Line (NWBS) to Unrestricted Line (NWBT)**

**Bethesda, MD** Northwest Biotherapeutics, Inc. (AIM: NWBS and NWBT; OTC BB: NWBO) announces today that 1,177,754 shares have been migrated to the unrestricted line (ISIN: US66737P5017) from the Reg S restricted line (ISIN: USU666161000).

The shares were transferred in the following amounts and on the following dates:

<b>Date of transfer</b>	<b>Number of shares</b>
30 November 2007	799
20 December 2007	133
15 September 2008	1,052,632
19 March 2009	2,000
7 April 2009	122,190

No new shares have been issued and the transfers arose by virtue of the expiration of the restrictions on the stock under U.S. securities law. Following the transfer of these shares, the Company has a total of 45,069,972 issued and outstanding common shares of 0.001 each in the Company. Following the transfers, 39,183,124 common shares of 0.001 each in the Company will be traded on AIM under the ticker NWBT, the "Reg S line" and 5,886,848 common shares of 0.001 each in the Company will be traded on AIM under the ticker NWBT, the "unrestricted line".

Dealings in the shares under the ticker NWBT are expected to commence trading on AIM on 12 May 2009.

**About Northwest Biotherapeutics**

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell-based vaccines, and therapeutic antibodies. The Company is currently conducting a large clinical trial

in Glioblastoma multiforme, which is designed and powered to serve as a pivotal trial. The Company has also received clearance from the FDA for a large Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in five other cancers. The Company also has a second technology platform, involving monoclonal antibodies to CXCR4, which is at the late pre-clinical development stage.

For further information, please visit the company web site at [www.nwbio.com](http://www.nwbio.com).

## **Disclaimer**

*Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated. Additional information on these and other factors, which could affect the company's results, is included in its Securities and Exchange Commission ("SEC") filings. Finally, there may be other factors not mentioned above or included in the company's SEC filings that may cause actual results to differ materially those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.*

## **For further information, please contact:**

### **Northwest Biotherapeutics, Inc.**

Alton L. Boynton, Chief Executive Officer

+1 240 497 9024

### **Buchanan Communications**

Lisa Baderoon ([lisab@buchanan.uk.com](mailto:lisab@buchanan.uk.com)) / Mary-Jane Johnson / +44 (0)20 7466 5000

Catherine Breen

### **Collins Stewart Europe Limited**

Adrian Hadden/ Adam Cowen

+44 (0)20 7523 8350

This information is provided by RNS  
The company news service from the London Stock Exchange